Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 15, 2018
Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event
TOKYO, Nov. 8, 2018 /PRNewswire/ -- Daiichi Sankyo, Inc. (Japan: 4568.T, OTC: DSNKY) based in Tokyo, Japan, and focused on pharmaceutical business, today announced that Daiichi Sankyo, Senior Director, IR group Mr. Junichi Onuma will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on 2018. This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors.
DATE: November 15th, 2018
TIME: 8:30 AM ET
This will be a live, interactive online event where investors are invited to ask international companies their questions in real-time and to download a company's information in their "virtual trade booth" in the Exhibits section. If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
Participation is free of charge.
It is recommended that investors pre-register to save time and receive event updates.
Recent Company Highlights
- 2018.11.06 EMA Validates and Grants Accelerated Assessment of Marketing Authorization Application for Daiichi Sankyo's FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML
- 2018.10.26 Daiichi Sankyo Announces Clinical Research Collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate [Fam-] Trastuzumab Deruxtecan (DS-8201) with Avelumab and a DNA Damage Response Inhibitor in Patients with HER2 Expressing and Mutated Solid Tumors
- 2018.10.22 Daiichi Sankyo Presents Updated Results of [Fam-] Trastuzumab Deruxtecan (DS-8201) in Patients with HER2 Expressing Advanced Colorectal Cancer at 2018 European Society for Medical Oncology (ESMO) Congress
About Daiichi Sankyo
[Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com.]
SOURCE Daiichi Sankyo
Company Codes: OTC-PINK:DSNKY, Tokyo:4568